MorphoSys Pins Hopes On Pelabresib For Near-Term Value After Tumultuous 2022
Cost-Cutting Measures In Place
Executive Summary
The German biotech has highlighted its myelofibrosis drug candidate, pelabresib, as a key value driver going forward after a year of hard knocks and lackluster Monjuvi sales that forced the firm to downsize its workforce and cease preclinical operations.